Entrada Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TRDA research report →
Range $11 – $17
Price Chart
About the company
Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range of neuromuscular ailments. The company leverages its proprietary EEV platform to cultivate a rich pipeline of therapeutic programs, integrating oligonucleotide, antibody, and enzyme-based approaches.
- CEO
- Dipal Doshi
- IPO
- 2021
- Employees
- 152
- HQ
- Boston, MA, US
Get TickerSpark's AI analysis on TRDA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $295.04M
- P/E
- -1.91
- PEG
- 0.03
- P/S
- 62.96
- P/B
- 1.37
- EV/EBITDA
- -1.48
- Div Yield
- 0.00%
- Gross Margin
- -754.72%
- Op Margin
- -3767.07%
- Net Margin
- -3537.73%
- ROE
- -57.61%
- ROIC
- -62.61%
Latest fiscal year · YoY change
- Revenue
- $25.42M-87.9%
- Gross Profit
- $21.32M-89.9%
- Op Income
- $-155,998,000
- Net Income
- $-143,750,000-319.0%
- EPS
- $-3.47-297.2%
- OCF Growth
- -209.2%
- FCF Growth
- -189.7%
- 52W High
- $16.45
- 52W Low
- $5.02
- 50D MA
- $6.94
- 200D MA
- $9.69
- Beta
- -0.26
- RSI (14)
- 58
- Avg Volume
- 365.07K
No earnings-call transcripts are available for TRDA yet.
- Free Float
- 57.2%
- Shares Outstanding
- 38.82M
- Float Shares
- 22.21M
of shares held by institutions
119 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Baker Bros. Advisors LP | 5.07M | 0 |
| Mpm Asset Management LLC | 4.38M | 0 |
| 5am Venture Management, LLC | 4.06M | 0 |
| Blackrock, Inc. | 2.58M | ▲ 224.54K |
| Merck & Co., Inc. | 1.74M | ▲ 1.74M |
| Vanguard Group Inc | 1.63M | ▲ 28.23K |
| Vanguard Capital Management LLC | 1.27M | ▲ 13.62K |
| Bioimpact Capital LLC | 1.25M | ▲ 1.25M |
| Tcg Crossover Management, LLC | 1.06M | ▼ 1.23M |
| Wellington Management Group Llp | 954.42K | ▼ 80.36K |
| Millennium Management LLC | 763.96K | ▲ 244.60K |
| Stepstone Group LP | 761.28K | 0 |
Held by 115 ETFs
Biggest fund positions in TRDA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 6, 26 | PARMAR KUSH | sell | 10,494 |
| Aug 7, 26 | PARMAR KUSH | sell | 52,317 |
| Aug 10, 26 | PARMAR KUSH | sell | 92,444 |
| Aug 6, 26 | 5AM Ventures V, L.P. | sell | 10,494 |
| Aug 7, 26 | 5AM Ventures V, L.P. | sell | 52,317 |
| Jul 30, 26 | 5AM Ventures V, L.P. | sell | 114,756 |
| Jul 31, 26 | 5AM Ventures V, L.P. | sell | 1,718 |
| Jul 30, 26 | PARMAR KUSH | sell | 114,756 |
| Jul 31, 26 | PARMAR KUSH | sell | 1,718 |
| Jun 10, 26 | PARMAR KUSH | other | 19,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our TRDA coverage
Recent articles, reports, and earnings notes.
No research on TRDA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TRDA report →Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Tops Revenue Estimates
zacks.com · Aug 5
Entrada Therapeutics Reports Second Quarter 2026 Financial Results
globenewswire.com · Aug 5
Entrada Therapeutics, Inc. (TRDA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
seekingalpha.com · Jun 8
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA
prnewswire.com · Jun 4
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA
globenewswire.com · Jun 2
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study
globenewswire.com · Jun 2
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics' ELEVATE-45-201 Study
globenewswire.com · Jun 2
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Jun 1
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.